Company Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.
MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Feb 8, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Yuichi Iwaki |
Contact Details
Address: 4275 Executive Square, Suite 300 La Jolla, California 92037 United States | |
| Phone | 858 373 1500 |
| Website | medicinova.com |
Stock Details
| Ticker Symbol | MNOV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001226616 |
| CUSIP Number | 58468P206 |
| ISIN Number | US58468P2065 |
| Employer ID | 33-0927979 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Senior Vice President, Chief Medical Officer and Director |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | PRER14A | Filing |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 10, 2026 | 10-K | Annual Report |
| Feb 20, 2026 | 8-K | Current Report |
| Dec 30, 2025 | 424B5 | Filing |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 11, 2025 | EFFECT | Notice of Effectiveness |